Abstract 283P
Background
Bone fracture is a devastating event in patients with mCRC. Nevertheless, no study has compared OF and PF in these patients.
Methods
We retrospectively analyzed clinical data of patients with mCRC who underwent palliative first-line oxaliplatin or irinotecan backbone chemotherapy at Seoul National University Bundang Hospital. This study aimed to identify the cumulative incidence rates of OF and PF in these patients and their risk factors.
Results
A total of 622 patients (male, 359) were consecutively enrolled between Jan. 2008 and Dec. 2015. The median age was 61 years (range, 20-91 years). Before palliative first-line chemotherapy (oxaliplatin backbone and irinotecan backbone in 313 [50.3%] and 309 [49.7%] patients, respectively), the median body mass index was 22.6 kg/m2 (range, 13.8-36.2 kg/m2) and bone metastasis was found in 42 patients (6.8%). During a median follow-up of 65.5 months (range 1.6-126.0 months), the median overall survival was 27.2 months (95% confidence interval [CI], 24.5-29.9 months). Among 81 patients (13.0%) who experienced OF or PF events, OF, PF, and both developed in 42 (6.8%), 36 (5.8%), and 3 (0.5%) patients, respectively. The cumulative incidence rates of OF and PF were 3.4% (95% CI, 2.2-5.0%) and 2.7% (95% CI, 1.7-4.3%) at 1 year, 4.5% (95% CI, 3.1-6.4%) and 4.2% (95% CI, 2.8-6.0%) at 2 years, and 5.6% (95% CI, 3.9-7.6%) and 5.1% (95% CI, 3.5-7.0%) at 3 years, respectively. The cumulative incidence rate of the first OF or PF was 6.0% (95% CI, 4.3-8.0%) at 1 year, 8.6% (95% CI, 6.6-11.0) at 2 years, and 10.4% (95% CI, 8.2-13.0%) at 3 years. The most common fracture sites were the lumbar spines (52.4%) in OF and the thoracic spines (50.0%) in PF, respectively. The OF risk was significantly higher in patients with age ≥ 65 years (hazard ratio [HR] 3.20 [95% CI, 1.73-5.92], p<0.001) while the PF risk was not significant between the age groups (HR 0.77 [95% CI, 0.40-1.49], p=0.430).
Conclusions
Fracture events were substantial in patients with mCRC who received palliative chemotherapy. Notably, the incidence of OF was comparable with that of PF. Therefore, OF should be considered in elderly patients with lumbar spine fractures.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
293P - Generic dabigatran for cancer-associated venous thromboembolism: Real-world data
Presenter: Fen Saj
Session: Poster viewing 04
294P - Cross-sectional analysis on cancer-related distress, belief in alternative medicine among cancer patients and attendants visiting a tertiary care center in Northern India
Presenter: Amit Sehrawat
Session: Poster viewing 04
296P - Osimertinib as adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC): Updated results from ADAURA
Presenter: Yi-Long Wu
Session: Poster viewing 04
297P - Transbronchial microwave ablation of early lung cancers and lung oligometastases: Mid-term results
Presenter: Joyce Chan
Session: Poster viewing 04
298P - Does trisegmentectomy have functional benefit over lobectomy? Comparative analysis of changes in lung function and volumetry among stage IA non-small cell lung cancer patients
Presenter: sumin shin
Session: Poster viewing 04
299P - Furmonertinib as adjuvant therapy in EGFR-mutated non-small cell lung cancer following radical lung cancer surgery
Presenter: Qingyi Zhang
Session: Poster viewing 04
300P - Real-world efficacy and safety of anlotinib in combination with PD-1/PD-L1 inhibitors as first-line or second-line treatment in advanced non-small cell lung cancer
Presenter: Xin Shang
Session: Poster viewing 04
301P - Oxygen desaturation during 6-min walk test: Implications for postoperative complications in non-small cell lung cancer patients with impaired lung function
Presenter: Hye Yun Park
Session: Poster viewing 04
302P - Treatment patterns in resectable early-stage NSCLC in Taiwan: Subgroup analysis of a global real-world study
Presenter: Jin-Yuan Shih
Session: Poster viewing 04